Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers.

BACKGROUND Telomerase activity is detectable in more than 85% of primary cancers. We determined telomerase activity in biopsy specimens obtained from biliary tract cancers to evaluate the clinical application of telomerase activity detection in combination with p53 immunostaining and routine histologic examination. METHODS Biopsy specimens obtained during percutaneous transhepatic cholangioscopy from 13 patients with cholangiocarcinoma, 3 patients with gallbladder carcinoma, and 4 patients with intrahepatic bile duct stones were evaluated by routine histologic examination, p53 immunostaining, and telomerase activity. Semiquantitative determination of telomerase activity was performed using a fluorescence-based telomeric repeat amplification protocol. RESULTS Thirteen of 16 specimens of malignant tissue had detectable telomerase activity, whereas no specimen of nonmalignant tissue had detectable telomerase activity. A p53 overexpression was recognized by immunostaining in 9 of 16 samples with cancers. Combining both telomerase activity and p53 overexpression resulted in the detection of all cancer with a sensitivity of 100%. There were no false-positive results by either modality (specificity 100%). CONCLUSIONS The detection of telomerase activity in biopsy specimens and p53 overexpression in combination with routine histologic examination may improve the diagnosis of biliary tract cancers. (Gastrointest Endosc 2000;52:380-6).

[1]  H. Niiyama,et al.  Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms , 1999, Cancer.

[2]  K. Ohyashiki,et al.  Improvement in detecting telomerase activity using silica-based resin treatment: An experience of urine in bladder carcinoma. , 1999, International journal of oncology.

[3]  T. Itoi,et al.  K‐ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers , 1999, Pathology international.

[4]  J. Burdick,et al.  In situ hybridization for telomerase RNA in routine cytologic brushings for the diagnosis of pancreaticobiliary malignancies. , 1998, Gastrointestinal endoscopy.

[5]  I. Maetani,et al.  Limitations of Percutaneous Transhepatic Cholangioscopy for the Diagnosis of the Intramural Extension of Bile Duct Carcinoma , 1998, Endoscopy.

[6]  T. Sugai,et al.  Assessment of the expression of p53, MIB‐1 (Ki‐67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct , 1998, Cancer.

[7]  S. Venitt,et al.  Detection of telomerase activity in human prostate: a diagnostic marker for prostatic cancer? , 1997, British journal of urology.

[8]  H. Hanai,et al.  Telomere length and telomerase activity in carcinogenesis of the stomach. , 1997, Japanese journal of clinical oncology.

[9]  T. Itoi,et al.  Correlation of p53 protein expression with gene mutation in gall‐bladder carcinomas , 1997, Pathology international.

[10]  C. S. Lee.  Ras p21 protein immunoreactivity and its relationship to p53 expression and prognosis in gallbladder and extrahepatic biliary carcinoma. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[12]  K. Washington,et al.  Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. , 2008, Liver.

[13]  J. Shay,et al.  A nonradioactive, fluorescence-based telomeric repeat amplification protocol to detect and quantitate telomerase activity. , 1996, Trends in genetics : TIG.

[14]  J. Shay,et al.  Comparison of the telomeric repeat amplification protocol (TRAP) to the new TRAP-eze telomerase detection kit , 1996 .

[15]  K. Nouso,et al.  Telomerase as a tool for the differential diagnosis of human hepatocellular carcinoma , 1996, Cancer.

[16]  K. Ohyashiki,et al.  Non‐radioisotopic and Semi‐quantitative Procedure for Terminal Repeat Amplification Protocol , 1996, Japanese journal of cancer research : Gann.

[17]  J. Shay,et al.  Telomerase activity in human cancer. , 1996, Current opinion in oncology.

[18]  S. Hanai,et al.  Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. , 1995, Cancer research.

[19]  T. Kawai,et al.  Experience with Percutaneous Electronic Choledochoscopy , 1995 .

[20]  J. Shay,et al.  Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP) , 1995 .

[21]  H. Watanabe,et al.  p53 Immunostaining distinguishes malignant from benign lesions of the gall‐bladder , 1995, Pathology international.

[22]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[23]  Y. Nimura,et al.  Staging of Biliary Carcinoma: Cholangiography and Cholangioscopy , 1993, Endoscopy.

[24]  I. Maetani,et al.  A Study of Malignant Bile Duct Stenosis Using Percutaneous Transhepatic Cholangioscopy , 1991 .

[25]  W. Chen.  International comparison of the mortalities of biliary tract cancer , 1990 .

[26]  G. Morin.  The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats , 1989, Cell.